Purchase this article with an account.
E. Takahashi, A. Hirata, Y. Inomata, T. Kawaji, M. Fukushima, H. Tanihara; Erythropoietin and Vascular Endothelial Growth Factor in the Vitreous Fluid of Patients with Various Vitreoretinal Diseases . Invest. Ophthalmol. Vis. Sci. 2003;44(13):4870.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: Erythropoietin (EPO) is known to protect neurons against ischemia and oxidative stress. Both EPO and vascular endothelial growth factor (VEGF) are upregulated by hypoxia-inducible factor (HIF-1). The purpose of this study is to investigate the concentration of EPO in the vitreous fluid of various vitreoretinal diseases and the association VEGF. Methods: Vitreous fluid samples were collected during vitreous surgery from 13 patients with proliferative diabetic retinopathy (PDR), 13 patients with macular edema due to retinal vein occulusion (BRVO), and 13 patients with idiopathic macular hole (MH). EPO levels were determined by using radioimmunoassay and VEGF levels were assessed by ELISA. Serum samples were obtained and assessed from 10 patients with PDR, 11 patients with BRVO and 9 patients with MH prior to vitreous surgery. Results: The intravitreal concentration of EPO was significantly higher in eyes with PDR (1128.3 ± 1070.7 mU/ml, mean ± standard deviation), in eyes with BRVO (333.0 ± 460.4 mU/ml) than in eyes with MH (33.9 ± 17.8 mU/ml) (P=0.002, P=0.035, respectively). The vitreous concentration of VEGF was also significantly higher in eyes with PDR (1530 ± 2970 pg/ml), in eyes with BRVO (895±1041 pg/ml) than in eyes with MH (18±2 pg/ml )(P<0.001,P=0.008 respectively). However, there was no correlation between EPO and VEGF in vitreous concentration of all groups. Serum concentrations of EPO and VEGF did not show any statistically significant differences among three groups. Conclusions: EPO and VEGF were upregulated in ischemic retinal diseases, such as PDR and BRVO, although they are not related. Serum diffusion may play a partial role in explaining no correlation between EPO and VEGF.
This PDF is available to Subscribers Only